Day: October 26, 2022

On August 31, 2013, Koppireddi, Satish; Komsani, Jayaram Reddy; Avula, Sreenivas; Pombala, Sujitha; Vasamsetti, Satishbabu; Kotamraju, Srigiridhar; Yadla, Rambabu published an article.SDS of cas: 31699-14-6 The title of the article was Novel 2-(2,4-dioxo-1,3-thiazolidin-5-yl)acetamides as antioxidant and/or anti-inflammatory compounds. And the article contained the following:

A series of novel N-(4-aryl-1,3-thiazol-2-yl)-2-(2,4-dioxo-1,3-thiazolidin-5-yl)acetamides(4a-k) I and N-(1,3-benzothiazol-2-yl)-2-(2,4-dioxo-1,3-thiazolidin-5-yl)acetamide derivatives (4l-o) II are synthesized and evaluated for their anti-inflammatory and antioxidant activity (DPPH radical scavenging, superoxide anion scavenging, lipid peroxide inhibition, erythrocyte hemolytic inhibition). Compounds 4k and 4l have exhibited good antioxidant activity in four assays, while compounds 4c, 4d, 4m, 4n and 4o have shown good DPPH radical scavenging efficacy. Compounds 4a, 4h, 4i, 4k, 4m and 4n have possessed excellent anti-inflammatory activity. N-[4-(o-methoxyphenyl)-1,3-thiazol-2-yl]-2-(2,4-dioxo-1,3-thiazolidin-5-yl)acetamide (4k) and N-(6-nitro-/methoxy-1,3-benzothiazol-2-yl)-2-(2,4-dioxo-1,3-thiazolidin-5-yl)acetamide (4m and 4n) have exhibited both antioxidant and anti-inflammatory activities. The experimental process involved the reaction of 2-Amino-4-(4-iodophenyl)thiazole(cas: 31699-14-6).SDS of cas: 31699-14-6

The Article related to dioxothiazolidinylacetamide antioxidant antiinflammatory, anti-inflammatory activity, erythrocyte hemolysis, lipid peroxidation, n-(1,3-benzothiazol-2-yl)-2-(2,4-dioxo-1,3-thiazolidin-5-yl)acetamide, n-(4-aryl-1,3-thiazol-2-yl)-2-(2,4-dioxo-1,3-thiazolidin-5-yl)acetamide, superoxide anion and dpph radical scavenging and other aspects.SDS of cas: 31699-14-6

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Stevanovic, Nevena; Zlatar, Matija; Novakovic, Irena; Pevec, Andrej; Radanovic, Dusanka; Matic, Ivana Z.; Djordjic Crnogorac, Marija; Stanojkovic, Tatjana; Vujcic, Miroslava; Gruden, Maja; Sladic, Dusan; Andjelkovic, Katarina; Turel, Iztok; Cobeljic, Bozidar published an article in 2022, the title of the article was Cu(II), Mn(II) and Zn(II) complexes of hydrazones with a quaternary ammonium moiety: synthesis, experimental and theoretical characterization and cytotoxic activity.Category: thiazole And the article contains the following content:

Cu(II), Mn(II) and Zn(II) complexes with N,N,N-trimethyl-2-oxo-2-(2-(1-(thiazol-2-yl)ethylidene)hydrazinyl)ethan-1-aminium chloride (HL1Cl) were synthesized and characterized by single-crystal x-ray diffraction, IR spectroscopy, elemental anal. and DFT calculations In all three complexes, a ligand (L1) is coordinated in a deprotonated formally neutral zwitterionic form via NNO donor set atoms. Cu(II) and Zn(II) form mononuclear pentacoordinated complexes [CuL1(N3)(CH3OH)]BF4 and [ZnL1(N3)2], resp., while Mn(II) forms a binuclear [Mn2L12(μ-1,1-N3)2(N3)2]·2CH3OH complex, with unusual distorted trigonal-prismatic geometry around the metal centers. The antimicrobial activity of these complexes was tested against a panel of Gram-neg. and Gram-pos. bacteria, two yeasts and one fungal strain. The binuclear Mn(II) complex showed antifungal activity of similar intensity to amphotericin B. Based on the results of the brine shrimp test and DPPH radical scavenging activity, the most active Cu(II) and Mn(II) complexes were selected for evaluation of cytotoxic activity against five malignant cancer cell lines (HeLa, A375, MCF7, PC-3 and A549) and one normal cell line HaCaT. Both complexes showed significant activity. It should be pointed out that the activity of the Mn(II) complex against the MCF7 breast cancer cell line is only slightly weaker than that of cisplatin, but with selectivity to the tumor cell line in comparison to normal HaCaT cells, which is non-existent in the case of cisplatin. The experimental process involved the reaction of 2-Acetylthiazole(cas: 24295-03-2).Category: thiazole

The Article related to transition metal quaternary ammonium thiazolyl hydrazone complex preparation, crystal structure transition metal quaternary ammonium thiazolyl hydrazone complex, antimicrobial activity transition metal quaternary ammonium thiazolyl hydrazone complex, antitumor activity transition metal quaternary ammonium thiazolyl hydrazone complex and other aspects.Category: thiazole

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On July 10, 2003, Lau, Jesper; Kodra, Janos Tibor; Guzel, Mustafa; Santosh, Kalpathy Chidambareswaran; Mjalli, Adnan M. M.; Andrews, Robert Carl; Polisetti, Dharma Rao published a patent.Safety of Methyl 2-(2-aminothiazol-4-yl)acetate The title of the patent was Preparation of N-aryl amide derivatives as glucokinase (GK) activators. And the patent contained the following:

Amides and ureas, such as R3-X-A(R1)-L1-G-NR4R5 [A = N, C(R2); G = SO2, CO; L1 = bond or linking alkylene, etc.; X = bond, O, S, SO, SO2, N(R6), alkylene, etc.; R1, R3 = H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, etc.; R2 = H, alkyl; R1R2 = cycloalkyl or heterocyclic ring; R4 = H, alkyl; R5 = aryl, heteroaryl; R6 = H, alkyl], were prepared as GK activators for therapeutic use in the treatment of diseases or conditions where increasing glucokinase activity is beneficial, such as impaired glucose tolerance (IGT), Syndrome X, type 2 diabetes, type 1 diabetes, dyslipidemia, hyperlipidemia, hypertension, and obesity. Thus, amide I was prepared via formation of 2-(3,4-dichlorophenoxy)hexanoic acid in 55% yield by reacting Et 2-hydroxyhexanoate with 3,4-dichlorophenol using Ph3P and diisopropyl azodicarboxylate in THF followed by formation of I in 72% by an amidation reaction of 2-(3,4-dichlorophenoxy)hexanoic acid with 2-aminothiazole using TFFH and DIEA in THF. The prepared amides were assayed for human liver GK activation activity. The experimental process involved the reaction of Methyl 2-(2-aminothiazol-4-yl)acetate(cas: 64987-16-2).Safety of Methyl 2-(2-aminothiazol-4-yl)acetate

The Article related to heterocyclic amide preparation glucokinase activator, impaired glucose tolerance treatment heterocyclyl amide preparation, syndrome x treatment heterocyclyl amide preparation, diabetes treatment heterocyclyl amide preparation, dyslipidemia treatment heterocyclyl amide preparation, hyperlipidemia treatment heterocyclyl amide preparation and other aspects.Safety of Methyl 2-(2-aminothiazol-4-yl)acetate

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On February 15, 2007, Nunes, Joseph J.; Milne, Jill; Bemis, Jean; Xie, Roger; Vu, Chi B.; Ng, Pui Yee; Disch, Jeremy S. published a patent.HPLC of Formula: 64987-16-2 The title of the patent was Preparation of imidazo[2,1-b]thiazole derivatives as sirtuin modulators. And the patent contained the following:

The title compounds I [R19 = 1,2-phenylene, 5-6 membered 1,2-heteroarylene; R20 = H or solubilizing group; R21 = (un)substituted NHCO, NHSO2, NHCONH, etc.; R31 = (un)substituted monocyclic or bicyclic (hetero)aryl; with provisos] and their analogs which are novel sirtuin-modulating compounds useful for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity, were prepared E.g., a 3-step synthesis of II, starting from 2-aminothiazole and 2-bromo-2′-nitroacetophenone, was given. Exemplified compounds I were tested for sirtuin modulating activity (data given). Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent. The experimental process involved the reaction of Methyl 2-(2-aminothiazol-4-yl)acetate(cas: 64987-16-2).HPLC of Formula: 64987-16-2

The Article related to benzimidazole preparation sirtuin modulator antidiabetic antiobesity cardiovascular antiinflammatory antitumor, thiazolopyridine preparation sirtuin modulator antidiabetic antiobesity cardiovascular antiinflammatory antitumor, oxazolopyridine preparation sirtuin modulator antidiabetic antiobesity cardiovascular antiinflammatory antitumor and other aspects.HPLC of Formula: 64987-16-2

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On February 15, 2007, Nunes, Joseph J.; Milne, Jill; Bemis, Jean; Xie, Roger; Vu, Chi B.; Ng, Pui Yee; Disch, Jeremy S. published a patent.Computed Properties of 64987-16-2 The title of the patent was Preparation of imidazopyridine derivatives as sirtuin modulators. And the patent contained the following:

The title compounds I [R23, R24 = H, Me or solubilizing agent; R25 = H or solubilizing agent; R19 = 1,2-phenylene, 5-membered heteroarylene; R21 = (un)substituted NHCO, NHSO2, NHCONH, etc.; R31 = (un)substituted monocyclic or bicyclic (hetero)aryl; with provisos] and their analogs which are novel sirtuin-modulating compounds useful for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity, were prepared E.g., a 3-step synthesis of II, starting from 2-bromo-2′-nitroacetophenone and 2-aminopyridine, was given. Exemplified compounds I were tested for sirtuin modulating activity (data given). Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent. The experimental process involved the reaction of Methyl 2-(2-aminothiazol-4-yl)acetate(cas: 64987-16-2).Computed Properties of 64987-16-2

The Article related to benzimidazole preparation sirtuin modulator antidiabetic antiobesity cardiovascular antiinflammatory antitumor, thiazolopyridine preparation sirtuin modulator antidiabetic antiobesity cardiovascular antiinflammatory antitumor, oxazolopyridine preparation sirtuin modulator antidiabetic antiobesity cardiovascular antiinflammatory antitumor and other aspects.Computed Properties of 64987-16-2

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On February 15, 2007, Nunes, Joseph J.; Milne, Jill; Bemis, Jean; Xie, Roger; Vu, Chi B.; Ng, Pui Yee; Disch, Jeremy S.; Salzmann, Thomas; Armistead, David published a patent.Reference of Methyl 2-(2-aminothiazol-4-yl)acetate The title of the patent was Preparation of oxazolopyridine derivatives as sirtuin modulators. And the patent contained the following:

The title compounds I [X7-X10 = N, CR20, CR22 (wherein R20 = H or solubilizing group; R22 = H, (un)substituted alkyl; one of X7-X10 = N and the others = CR20 or CR22; zero to one R20 is solubilizing group); R19 = 1,2-phenylene, pyridylene, 5-6 membered (hetero)arylene; R21 = (un)substituted NHCO, NHSO2, NHCONH, etc.; R31 = (un)substituted monocyclic or bicyclic (hetero)aryl; with provisos] and their analogs which are novel sirtuin-modulating compounds useful for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity, were prepared E.g., a 3-step synthesis of II, starting from 2-chloropyridin-3-amine and 3-nitrobenzoyl chloride, was given. Exemplified compounds I were tested for sirtuin modulating activity (data given). Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent. The experimental process involved the reaction of Methyl 2-(2-aminothiazol-4-yl)acetate(cas: 64987-16-2).Reference of Methyl 2-(2-aminothiazol-4-yl)acetate

The Article related to benzimidazole preparation sirtuin modulator antidiabetic antiobesity cardiovascular antiinflammatory antitumor, thiazolopyridine preparation sirtuin modulator antidiabetic antiobesity cardiovascular antiinflammatory antitumor, oxazolopyridine preparation sirtuin modulator antidiabetic antiobesity cardiovascular antiinflammatory antitumor and other aspects.Reference of Methyl 2-(2-aminothiazol-4-yl)acetate

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On February 15, 2007, Nunes, Joseph J.; Milne, Jill; Bemis, Jean; Xie, Roger; Vu, Chi B.; Ng, Pui Yee; Disch, Jeremy S. published a patent.Application In Synthesis of Methyl 2-(2-aminothiazol-4-yl)acetate The title of the patent was Preparation of benzimidazole derivatives as sirtuin modulators. And the patent contained the following:

The title compounds I [R1, R4, R6 = H or (un)substituted alkyl; R2 = (un)substituted NHCO, NHSO2, NHCONH, etc.; R3 = (un)substituted monocyclic or bicyclic (hetero)aryl; R5, R7 = H or solubilizing group; with provisos] and their analogs which are novel sirtuin-modulating compounds useful for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity, were prepared E.g., a 2-step synthesis of II, starting from 1,2-diaminobenzene and 6-aminopyridine-2-carboxylic acid, was given. Exemplified compounds I were tested for sirtuin modulating activity (data given). Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent. The experimental process involved the reaction of Methyl 2-(2-aminothiazol-4-yl)acetate(cas: 64987-16-2).Application In Synthesis of Methyl 2-(2-aminothiazol-4-yl)acetate

The Article related to benzimidazole preparation sirtuin modulator antidiabetic antiobesity cardiovascular antiinflammatory antitumor, thiazolopyridine preparation sirtuin modulator antidiabetic antiobesity cardiovascular antiinflammatory antitumor, oxazolopyridine preparation sirtuin modulator antidiabetic antiobesity cardiovascular antiinflammatory antitumor and other aspects.Application In Synthesis of Methyl 2-(2-aminothiazol-4-yl)acetate

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On December 31, 2021, Stevanovic, Nevena; Mazzeo, Paolo Pio; Bacchi, Alessia; Matic, Ivana Z.; Djordjic Crnogorac, Marija; Stanojkovic, Tatjana; Vujcic, Miroslava; Novakovic, Irena; Radanovic, Dusanka; Sumar-Ristovic, Maja; Sladic, Dusan; Cobeljic, Bofzidar; Andjelkovic, Katarina published an article.Name: 2-Acetylthiazole The title of the article was Synthesis, characterization, antimicrobial and cytotoxic activity and DNA-binding properties of d-metal complexes with hydrazones of Girard’s T and P reagents. And the article contained the following:

In this work synthesis, characterization and crystal structures of 1, Zn(II) complex ([ZnL1(NCS)2]), with (E)-1-(2-oxo-2-(2-(quinolin-2-ylmethylene)hydrazinyl)ethyl)pyridin-1-ium chloride (HL1Cl) and 2, Bi(III) complex ([BiHL2Cl4]x1/2CH3OH), with (E)-N,N,N-trimethyl-2-oxo-2-(2-(1-(thiazol-2-yl)ethylidene)hydrazinyl)ethan-1-aminium chloride (HL2Cl), have been reported. Zn(II) complex possesses a distorted trigonal bipyramidal geometry while surroundings around Bi(III) ion are extended pentagonal bipyramidal. Antimicrobial activity, brine shrimp assay and DPPH radical scavenging activity of both complexes, including previously synthesized complexes with HL2Cl ligand (Zn(II) and Ni(II)) and complexes with (E)-N,N,N-trimethyl-2-oxo-2-(2-(1-(pyridin-2-yl)ethylidene)hydrazinyl)ethan-1-aminium chloride (HL3Cl) (Zn(II), Cu(II), Cd(II), Co(II), Fe(III), Ni(II)), were evaluated. For the most active complexes, cytotoxic activity against five malignant cancer cell lines (HeLa, A375, MCF7, PC-3 and A549) and normal cell line HaCaT, as well as generation of reactive oxygen species (ROS), was tested. The experimental process involved the reaction of 2-Acetylthiazole(cas: 24295-03-2).Name: 2-Acetylthiazole

The Article related to quinolinylmethylene hydrazinylpyridinium zinc thiocyanide complex preparation crystal mol structure, thiazolylethylidene hydrazinylethylaminium bismuth complex preparation crystal mol structure antimicrobial, cytotoxic dna complexation metal hydrazone girard t p reagent, antimicrobial activity, cytotoxic activity, dna-binding experiments and other aspects.Name: 2-Acetylthiazole

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On September 4, 1997, Jeon, Yoon T.; Gluchowski, Charles published a patent.SDS of cas: 70202-00-5 The title of the patent was Preparation of novel indoles and benzothiazoles for cloned human alpha 2 receptors. And the patent contained the following:

The title compounds [I-IV; R1-R3 = H, C1-7 alkyl, C2-7 alkenyl, alkynyl; R4-R6 = H, halo, Oh, etc.; R7 = H, NH, C1-7 alkyl, etc.; R8 = H, C1-7 alkyl, C2-7 alkenyl, etc.; R9 = H, Ph, C1-7 alkyl, etc.; X = CH2, O, NH, S] which are selective for cloned human alpha 2 receptors and therefore useful for lowering intraocular pressure, for treating presbyopia, migraine, hypertension, alc. withdrawal, drug addiction, rheumatoid arthritis, ischemic pain, spasticity, diarrhea, nasal congestion, urinary incontinence as well as for use as analgesics, sedatives, anesthetics, cognition enhancers and ocular vasoconstriction agents, were prepared Thus, reaction of 7-bromo-5-aminoindole with 2-imidazoline-2-sulfonic acid (ISA) afforded 46% I [R1-R5 = H; R6 = Br; R7-R9 = H; X = N] which showed pEC50 of 9.36 at alpha 2 receptor. The experimental process involved the reaction of 7-chloro-benzothiazol-6-ylamine(cas: 70202-00-5).SDS of cas: 70202-00-5

The Article related to adrenoceptor agonist indole benzothiazole preparation, anesthetic indole benzothiazole preparation, sedative indole benzothiazole preparation, vasoconstriction ocular indole benzothiazole preparation, antiglaucoma agent indole benzothiazole preparation, migraine indole benzothiazole preparation, antihypertensive indole benzothiazole preparation and other aspects.SDS of cas: 70202-00-5

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On August 16, 2001, Fotouhi, Nader; Gillespie, Paul; Guthrie, Robert William; Pietranico-Cole, Sherrie Lynn; Yun, Weiya published a patent.Synthetic Route of 19989-66-3 The title of the patent was Preparation of N-aroyldehydroamino acids as lymphocyte function associated antigen-1 antagonists.. And the patent contained the following:

Title compounds [I; R1 = H, OH, amino, halo; R2 = H, OH, halo; R3 = H; R2R3 = atoms to form Ph, pyrrole, pyrroline, pyrazole, triazole, imidazole, etc., rings; A = CH2CH2CH(OH), CH2CH2CO, CH2NHCO, etc.; R4, R5 = H, Me, Et; B = H, alkyl, (substituted) (bicyclic) (hetero)aryl, etc.; R6 = CO2H, CO2R7, CH2OH, etc.; R7 = alkyl, dimethylaminoalkyl, pyrrolidinylalkyl, etc.], were prepared Thus, Me (Z)-3-(1H-benzotriazol-5-yl)-2-[[2-chloro-4-[[(3-hydroxybenzyl)amino]carbonyl]-6-methylbenzoyl]amino]propenoate (preparation given) was stirred 125 h with LiOH in MeOH/THF/H2O to give 61% (Z)-3-(1H-benzotriazol-5-yl)-2-[[2-chloro-4-[[(3-hydroxybenzyl)amino]carbonyl]-6-methylbenzoyl]amino]propenoic acid. The latter inhibited LFA-1 binding to immobilized ICAM-1 with IC50 = 0.4 nM. The experimental process involved the reaction of Benzo[d]thiazol-6-ylmethanol(cas: 19989-66-3).Synthetic Route of 19989-66-3

The Article related to aroyldehydroamino acid preparation lymphocyte function associated antigen antagonist, propenoate aroylamino preparation lfa1 antagonist, amino acid dehydro aroyl lymphocyte function associated antigen antagonist, t cell activation inhibitor aroylaminopropenoate preparation, psoriasis graft rejection dermatitis asthma arthritis treatment aroylaminopropenoate and other aspects.Synthetic Route of 19989-66-3

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica